Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2011-01-18
2011-01-18
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S317000, C514S563000, C514S593000, C514S604000, C514S870000, C514S401000
Reexamination Certificate
active
07872048
ABSTRACT:
The present invention is directed to therapeutic compositions targeting the NCCa-ATPchannel of an astrocyte, neuron or capillary endothelial cell and methods of using same. More specifically, antagonists of the NCCa-ATPchannel are contemplated. The compositions are used to prevent cell death and to treat secondary damage associated with spinal cord injury.
REFERENCES:
patent: 5047429 (1991-09-01), Nye
patent: 5166162 (1992-11-01), Masereel et al.
patent: 5215985 (1993-06-01), Murphy et al.
patent: 5236932 (1993-08-01), Greenfield et al.
patent: 5281599 (1994-01-01), Murphy et al.
patent: 5451580 (1995-09-01), Murphy et al.
patent: 5545656 (1996-08-01), Loose et al.
patent: 5677344 (1997-10-01), Greenfield et al.
patent: 5811393 (1998-09-01), Klagsbrun et al.
patent: 5849796 (1998-12-01), Gericke et al.
patent: 5916871 (1999-06-01), Johnson
patent: 5929082 (1999-07-01), Chambers et al.
patent: 5962645 (1999-10-01), Keay et al.
patent: 6043224 (2000-03-01), Lee et al.
patent: 6100047 (2000-08-01), Wilkison et al.
patent: 6156522 (2000-12-01), Keay et al.
patent: 6184248 (2001-02-01), Lee et al.
patent: 6187756 (2001-02-01), Lee et al.
patent: 6232289 (2001-05-01), Keay et al.
patent: 6242200 (2001-06-01), Wilkison et al.
patent: 6372743 (2002-04-01), Darrow et al.
patent: 6376197 (2002-04-01), Keay et al.
patent: 6469055 (2002-10-01), Lee et al.
patent: 6492130 (2002-12-01), Wilkison et al.
patent: 6492339 (2002-12-01), Sleevi et al.
patent: 6511989 (2003-01-01), Heitsch et al.
patent: 6569633 (2003-05-01), Wilkison et al.
patent: 6569845 (2003-05-01), Futamura et al.
patent: 6596751 (2003-07-01), Fujita et al.
patent: 6610746 (2003-08-01), Fryburg et al.
patent: 6613785 (2003-09-01), Bril et al.
patent: 6679859 (2004-01-01), Keipert et al.
patent: 2001/0003751 (2001-06-01), Terashita et al.
patent: 2001/0016586 (2001-08-01), Guitard et al.
patent: 2002/0013268 (2002-01-01), Fryburg et al.
patent: 2002/0037928 (2002-03-01), Jaen et al.
patent: 2002/0065315 (2002-05-01), Jensen et al.
patent: 2002/0081306 (2002-06-01), Elliott et al.
patent: 2002/0094977 (2002-07-01), Robl et al.
patent: 2003/0215889 (2003-11-01), Simard et al.
patent: 2003/0216294 (2003-11-01), Fryburg et al.
patent: 2007/0203239 (2007-08-01), Gehenne et al.
patent: 1782815 (2007-05-01), None
patent: WO 01/54771 (2001-08-01), None
patent: WO-03/075933 (2003-09-01), None
patent: WO-03/079987 (2003-10-01), None
patent: WO/2006/000608 (2006-01-01), None
patent: WO-2007 058902 (2007-05-01), None
Simard et al (2007. Journal of Clinical Investigation. 117(8): 2105-2113).
Haider et al, 2007. The EMBO Journal. 26: 3749-3759.
Phillips, A., J Pharm Pharmacology 53: 1169-1174, 2001.
Vidal et al. 2005. European Journal of Cancer. 41: 2812-2818.
Schmitt et al, 2002 (“Endocrine and Metabolic Consequences of Spinal Cord Injuries”, Chapter 18 in Spinal Cord Medicine: principles and practices. 2002). pp. 221-235.
Gribble et al, 2003. Diabetologia. 46: 875-891.
Aguilar-Bryan et al., “Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion,”Science, 268: 423-426, 1995.
Ahmad et al., “Mouse cortical collecting duct cells show nonselective cation channel activity and express a gene related to the cGMP-gated rod photoreceptor channel,”Proc. Natl. Acad. Sci. USA, 89: 10262-10266, 1992.
Angel et al., “The binding site for [3H]glibenclamide in the rat cerebral cortex does not recognize K-channel agonists or antagonists other than sulphonylureas,”Fundam. Clin. Pharmacol, 5(2): 107-15, 1991.
Armijo, “Advances in the physiopathology of epilegtogenesis: molecular aspects,”Rev. Neurol., 34(5): 409-29, 2002.
Auger, G. et al; Purification and Partial Characterization of a Hepatocyte Antiproliferative Glycopeptide, Journal of Cellular Biochemistry, (1989) vol. 40, pp. 439-451.
Ballerini, “Glial cells express multiple ATP binding cassette proteins which are involved in ATP release,”Neuroreport, 13(14): 1789-92, 2002.
Bareyre et al., “Inflammation, degeneration and regeneration in the injured spinal cord: insights from DNA microarrays,”Trends Neurosci., 26(10): 555-563, 2003.
Bartholdi et al., “Expression of pro-inflammatory cytokine and chemokine mRNA upon experimental spinal cord injury in mouse: an in situ hybridization study,”Eur. J. Neurosci., 9(7): 1422-1438, 1997.
Baudelet et al., “Evidence for a Neuroprotective Effect of Pyrid-3-yl-sulphonyl-urea in Photochemically Induced Focal Ischaemia in Rats: Magnetic Resonance Imaging Evaluation,”J. Pharm. Pharmacol., 51: 967-970, 1999.
Beier-Holgersen, R., “The in vitro cytotoxicity of urine from patients with interstitial cystitis”, Journal of Urology (Jan. 1994), vol. 151, pp. 206-207.
Bevan et al, “Voltage Gasted Ionic Channels in Rat Cultured Astrocytes, Reactive Astrocytes and an Astrocyte-oligodendrocyte Progenitor Cell, ” J. Physiol vol. 82, 1987, pp. 327-335.
Champigny et al., “A voltage, calcium, and ATP sensitive non selective cation channel in human colonic tumor cells,”Biochem. Biophys. Res. Commun., 176: 1196-1203, 1991.
Chen et al, “Cell Swelling and a Nonselective Cation Channel Regulated by Internal CA2+ and ATP in Native Reactive Astrocytes from Adult Rat Brain,” The Journal of Neuroscience vol. 21 No. 17, Sep. 1, 2001, pp. 6512-6521.
Chen et al., “A Calcium-Activated Nonspecific Cation Channel in Reactive Astrocytes from Adult Rat Brain,” Society for Neuroscience Abstracts, vol. 26, No. 1-2, Abstract No. 791.1, 2000 [abstract].
Chen et al., “Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain,”J. Neurosci., 23: 8568-8577, 2003.
Copin et al., “70-kDa heat shock protein expression in cultured rat astrocytes after hypoxia: regulatory effect of almitrine,”Neurochem. Res., 20(1): 11-15, 1995.
Csanady et al., “Ca(2+)- and voltage-dependent gating of Ca(2+)- and ATP-sensitive cationic channels in brain capillary endothelium,”Biophys. J., 85: 313-327, 2003.
Currie et al., “Benign focal ischemic preconditioning induces neuronal Hsp70 and prolonged astrogliosis with expression of Hsp27,”Brain Res., 863(1-2): 169-181, 2000.
Davies, “Insulin secretagogues,”Curr. Med. Res. Opin. 18 Suppl., 1: ss22-30, 2002.
Fujita et al., “Molecular aspects of ATP-sensitive K+ channels in the cardiovascular system and K+ channel openers,”Pharmacol. Ther., 85: 39-53, 2000.
Gopalakrishnan et al., “Pharmacological characterization of a 1,4-dihydropyridine analogue, 9-(3,4-dichorophenyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahydro-1,8(2H,5H)-acridinedione (A-184209) as a novelK(ATP) channel inhibitor,”Br. J. Pharmacol., 138(2): 393-99, 2003.
Gray et al., “Non-selective cation channel on pancreatic duct cells,”Biochem. Biophys. Acta, 1029:33-42, 1990.
Gribble et al., “Differential selectivity of insulin secretagogues. Mechanisms, clinical implications, and drug interactions,”J. Diabetes Complications, 17(2 Suppl): 11-5, 2003.
Gribble et al., “Tissue Specificity of Sulfonylureas: Studies on Cloned Cardiac and B-Cells K-ATP Channels,”Diabetes, 47: 1412-1418, 1998.
Hambrock et al., “Four novel splice variants of sulfonylurea receptor 1,”Am. J. Physiol. Cell Physiol., 283: C587-C598, 2002.
Hernandez-Sanchez et al., “Mice transgenically overexpressing sulfonylurea receptor 1 in forebrain resist seizure induction and excitotoxic neuron death,”PNAS, 98(6): 3549-3554, 2001.
Inagaki et al., “A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels,”Neuron, 16: 1011-1017, 1996.
Isomoto et al., “A novel sulfonylurea receptor forms with BIR (Kir6.2) a smooth muscle type ATP-sensitive K+ channel,”J. Biol. Chem., 271: 24321-24324, 1996.
Jarvis et al., “Purinergic Mechan
Fulbright & Jaworski L.L.P.
Howard Zachary C
Landsman Robert
University of Maryland Baltimore
LandOfFree
Methods for treating spinal cord injury with a compound that... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating spinal cord injury with a compound that..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating spinal cord injury with a compound that... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2684130